Not symptom‐free or no symptom improvement · patients with functional dyspepsia
It is very uncertain whether prokinetic changes not symptom‐free or no symptom improvement compared with placebo (very low certainty).
1 finding from 1 review
Post‐treatment symptoms scores · patients with functional dyspepsia
1 finding from 1 review
Mean difference symptoms scores · patients with functional dyspepsia
1 finding from 1 review
QoL · patients with functional dyspepsia
1 finding from 1 review
Adverse events · patients with functional dyspepsia
It is very uncertain whether prokinetic changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Not symptom‐free or no symptom improvement · patients with functional dyspepsia
It is very uncertain whether other prokinetics changes not symptom‐free or no symptoms improvement (itopride 50 three times… compared with domperidone 10mg three times a day (very low certainty).
1 finding from 1 review
Post‐treatment scores · patients with functional dyspepsia
1 finding from 1 review
Mean difference symptoms scores · patients with functional dyspepsia
1 finding from 1 review
Adverse events · patients with functional dyspepsia
It is very uncertain whether other prokinetics changes adverse events compared with domperidone 10mg three times a day (very low certainty).
1 finding from 1 review
Global symptoms of dyspepsia · adults with functional dyspepsia
Proton pump inhibitors plus prokinetics showed no clear difference in global symptoms of dyspepsia compared with prokinetics alone (moderate certainty).
1 finding from 1 review
Quality of life Korean version of the dyspepsia related Nepean Dyspepsia Index (0 to 99) and Functional Digestive Disorders Quality of Life questionnaire (FDDQL) scale · adults with functional dyspepsia
1 finding from 1 review
Adverse events · adults with functional dyspepsia
Proton pump inhibitors plus prokinetics probably leads to lower adverse events compared with prokinetics alone (moderate certainty).
1 finding from 1 review
Intervention not reported
Prokinetic versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
1 finding from 1 review
Intervention not reported
PPI versus prokinetic · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention may leads to lower PPI versus prokinetic (low certainty).
1 finding from 1 review
Intervention not reported
PPI versus prokinetic · patients with heartburn remission in endoscopy negative reflux disease
The intervention may leads to lower PPI versus prokinetic (low certainty).
1 finding from 1 review
Global symptoms of dyspepsia · adults with functional dyspepsia
Proton pump inhibitors (PPI) may leads to lower global symptoms of dyspepsia compared with prokinetics (low certainty).
1 finding from 1 review
Quality of life Korean version of the dyspepsia related Nepean Dyspepsia Index (NDI) from: 0 to 99 · adults with functional dyspepsia
1 finding from 1 review
Adverse events · adults with functional dyspepsia
Proton pump inhibitors (PPI) showed no clear difference in adverse events compared with prokinetics (moderate certainty).
1 finding from 1 review
Intervention not reported
PPI versus placebo Symptomatic outcome measures · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention leads to lower PPI versus placebo Symptomatic outcome measures (high certainty).
1 finding from 1 review
Intervention not reported
H2RA versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention probably leads to lower H2RA versus placebo (moderate certainty).
1 finding from 1 review